Position in ANL
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$846,046
+$844,516 QoQ
Shares Held
122,261
+11241.5% QoQ
Ownership
0.190%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ANL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026UBS Group AG holds $8,307,109,707 across 562 Biotechnology names. ANL ranks #255 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
22,619,472 | $626,559,372 | |
| 2 | PTGX |
Protagonist Therapeutics, Inc
|
5,177,796 | $545,739,697 | |
| 3 | ABVX |
Abivax S.A.
|
4,547,406 | $506,353,656 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
4,386,791 | $426,615,424 | |
| 5 | INSM |
INSMED Inc
|
1,737,481 | $284,112,890 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
630,618 | $281,596,158 | |
| 7 | APLS |
Apellis Pharmaceuticals, Inc.
|
6,206,681 | $249,694,775 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
299,979 | $231,775,770 |
All Filings in ANL
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $846,046 | 122,261 | Shares | Defined | 2026-05-05 | |
| 2025-12-31 | $1,530 | 1,078 | Shares | Defined | 2026-01-29 | |
| 2025-09-30 | $7,718 | 4,291 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $7,808 | 5,312 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $9,396 | 4,675 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $2 | 1 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $2,258 | 1,138 | Shares | Sole | 2024-11-14 | |
| 2023-09-30 | $8,775 | 585 | Shares | Sole | 2023-11-09 | |
| No filing history on record for this holder in this stock. | ||||||